Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Every Two Weeks in Patients with Type 2 Diabetes: a Multicenter, Randomized, Open-Label Study

NCT06900075 is registered in ClinicalTrials.gov with Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT06900075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06900075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Every Two Weeks in Patients with Type 2 Diabetes: a Multicenter, Randomized, Open-Label Study
Lead sponsor
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
July 30, 2025
Completion date
March 31, 2026
Enrollment
88 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes